Affinity Asset Advisors’s Acceleron Pharma XLRN Stock Holding History

Affinity Asset Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-35,350	Closed	-$6.08M	–	83
2021 Q3	$6.08M	Sell	35,350 -19,650	-36%	-$2.57M	1.54%	14
2021 Q2	$6.9M	Buy	55,000 +10,000	+22%	+$1.26M	2.47%	12
2021 Q1	$6.1M	Hold	45,000	–	–	2.07%	11
2020 Q4	$5.76M	Buy	+45,000	New	+$5.28M	3.05%	8

Affinity Asset Advisors's XLRN Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 35,350 shares — an estimated $6.08M sold.

Affinity Asset Advisors first reported a position in XLRN in Q4 2020 and held it in 4 quarters. The position peaked at $6.9M in Q2 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Affinity Asset Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Affinity Asset Advisors sold 35,350 Acceleron Pharma shares in Q4 2021, an estimated $6.08M.
Affinity Asset Advisors first reported a position in Acceleron Pharma in Q4 2020 and held it in 4 quarters.
Affinity Asset Advisors's Acceleron Pharma position peaked at $6.9M in Q2 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.